Connect to other sites within the UBM Medica Network
Zoledronate Fails to Improve Outcomes With Chemo in Osteosarcoma
Zoledronate in combination with chemotherapy failed to improve outcomes over chemotherapy alone in patients with osteosarcoma.
Three SNPs Associated With Overall Survival in Pediatric Ewing Sarcoma
Three single-nucleotide polymorphisms were identified that are significantly associated with OS in two separate cohorts of pediatric Ewing sarcoma patients.
Anlotinib Offers Efficacy Across Subtypes of Soft-Tissue Sarcoma
A phase II trial showed that the tyrosine kinase inhibitor anlotinib has promising efficacy across a variety of subtypes of advanced refractory soft-tissue sarcoma.
Novel Drug Combination Shows Activity in Angiosarcoma
A combination of the endoglin antibody TRC105 and pazopanib shows promising activity in patients with advanced soft-tissue sarcoma, particularly angiosarcoma.
Quality of Life Could Help Select Treatment for Soft-Tissue Sarcoma
Understanding quality of life and the detrimental impact of disease progression is critical for long-term care and survival of patients with soft-tissue sarcoma.
Gemcitabine Plus Pazopanib Shows Promise in Soft-Tissue Sarcomas
Combined therapy with gemcitabine and pazopanib appears to be a viable treatment option for patients with soft-tissue sarcomas refractory to anthracycline or ifosfamide.
Regorafenib Ups Progression-Free Survival in Several Soft-Tissue Sarcomas
Regorafenib is associated with improved progression-free survival in pretreated patients with advanced refractory non-liposarcoma soft-tissue sarcomas.
Drug Shows 10-Month Survival Improvement in Sarcoma
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
Slide Show: Gastrointestinal Stromal Tumors
This slide show features a CT image, and pathology images of gastrointestinal stromal tumors (GISTs) arising in the stomach using H&E, CD34, and c-Kit staining.
By clicking Accept, you agree to become a member of the UBM Medica Community.